Last update 08 May 2025

Recombinant human histone H1.3(SymBio Pharmaceuticals)

Overview

Basic Info

Drug Type
Recombinant protein
Synonyms
OncoHist, Product F
+ [2]
Target
Histone H1
Action
stimulants, modulators
Mechanism
Histone H1 stimulants, Apoptosis stimulants, Cell membrane modulators
Therapeutic Areas
NeoplasmsImmune System DiseasesHemic and Lymphatic Diseases
Active Indication
Acute Myeloid LeukemiaNon-Hodgkin Lymphoma
Inactive Indication-
Originator Organization
SymBio Pharmaceuticals Ltd.SymBio Pharmaceuticals Ltd.
Active Organization
Xenetic Biosciences, Inc.Xenetic Biosciences, Inc.Pharmsynthez PJSCPharmsynthez PJSCDana-Farber Cancer Institute, Inc.Dana-Farber Cancer Institute, Inc.
+ [1]
Inactive Organization-
License Organization-
Drug Highest PhasePhase 2
First Approval Date-
Regulation-
Login to view timeline

Related

100 Clinical Results associated with Recombinant human histone H1.3(SymBio Pharmaceuticals)
Login to view more data
100 Translational Medicine associated with Recombinant human histone H1.3(SymBio Pharmaceuticals)
Login to view more data
100 Patents (Medical) associated with Recombinant human histone H1.3(SymBio Pharmaceuticals)
Login to view more data
100 Deals associated with Recombinant human histone H1.3(SymBio Pharmaceuticals)
Login to view more data

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Acute Myeloid LeukemiaPhase 2-
SymBio Pharmaceuticals Ltd.SymBio Pharmaceuticals Ltd.
-
Acute Myeloid LeukemiaPhase 2-
Dana-Farber Cancer Institute, Inc.Dana-Farber Cancer Institute, Inc.
-
Acute Myeloid LeukemiaPhase 2-
Pharmsynthez PJSCPharmsynthez PJSC
-
Acute Myeloid LeukemiaPhase 2-
Xenetic Biosciences, Inc.Xenetic Biosciences, Inc.
-
Non-Hodgkin LymphomaPhase 2-
SymBio Pharmaceuticals Ltd.SymBio Pharmaceuticals Ltd.
-
Non-Hodgkin LymphomaPhase 2-
Dana-Farber Cancer Institute, Inc.Dana-Farber Cancer Institute, Inc.
-
Non-Hodgkin LymphomaPhase 2-
Xenetic Biosciences, Inc.Xenetic Biosciences, Inc.
-
Non-Hodgkin LymphomaPhase 2-
Pharmsynthez PJSCPharmsynthez PJSC
-
Acute Myeloid LeukemiaDiscovery
Russia
--
Acute Myeloid LeukemiaDiscovery
Germany
--
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
ASCO2009
Phase 1
HR-positive/HER2-low Solid Tumors
74
FOLFIRI + F
(nhydklirxu) = emopgywsfd kmmyhrfhen (ucauaqpaze )
-
20 May 2009
ASCO2006
Not Applicable
Recurrent Prostate Carcinoma
26
CAB+F
hwaqxfkbrv(awqhclqcyp) = onmwogjokk wtqjixflcw (xxjezgnclk )
View more
-
20 Jun 2006
hwaqxfkbrv(awqhclqcyp) = bfnrnlcfld wtqjixflcw (xxjezgnclk )
View more
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
login
or
view full example data
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
login
or
view full example data
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
login
or
view full example data
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
login
or
view full example data
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
login
or
view full example data
Accelerate your research with the latest regulatory approval information.

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.
login
or
view full example data
Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

Regulation

Understand key drug designations in just a few clicks with Synapse.
login
or
view full example data
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free